IMI launches call seventeen

The JTI Innovative Medicines Initiative 2 (IMI JU) has launched its seventeenth call for proposals. The indicative budget available for the 17th call with identifier H2020-JTI-IMI2-2019-17-two-stage is € 83,894,139: from EFPIA companies and IMI2 Associated Partners € 43,108,139 and from the IMI2 JU € 40,786,000. The Stage 1 submission deadline is April 25, 2019.

Call 17 includes three topics:

• Topic 1: Optimising future obesity treatment;
• Topic 2: Open access chemogenomics library and chemical probes for the druggable genome;
• Topic 3: Intelligent prediction and identification of environmental risks posed by human medicinal products.

The goal of the IMI2 is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI. Like IMI, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe's pharmaceutical industry.